Optic nerve

Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology

Retrieved on: 
Thursday, July 7, 2022
Mont Blanc, Kepler, Optic nerve, Pharmacology, Patient, Glaucoma, Therapy, COX, Severe cognitive impairment, Bimatoprost, Allergic conjunctivitis, Johannes Kepler, Retina, Nitric oxide, Disease, NO, NCX, AbbVie, LLC, Hemodynamics, Duane syndrome, Drainage, Euronext Paris, IOP, Ocular hypertension, Intraocular pressure, Fluticasone, Compartment, Erosion (morphology), Volkmann's contracture, Bausch & Lomb, Eye, Denali, Pharmaceutical industry

The publication NCX 470 restores ocular hemodynamics and retinal cell physiology after ET-1-induced ischemia/reperfusion injury of optic nerve and retina in rabbits by Bastia et al.

Key Points: 
  • The publication NCX 470 restores ocular hemodynamics and retinal cell physiology after ET-1-induced ischemia/reperfusion injury of optic nerve and retina in rabbits by Bastia et al.
  • Based on recently published Phase 2 results, NCX 470 potentially has best-in-class intraocular pressure lowering efficacy in patients with open angle glaucoma or ocular hypertension, said Doug Hubatsch, Chief Scientific Officer of Nicox.
  • NCX 470 is currently being evaluated in two multi-regional Phase 3 clinical trials, Mont Blanc and Denali.
  • NCX 470 is in development to reduce IOP in patients with open-angle glaucoma or ocular hypertension.

Graybug to Present at the 2022 OIS Retina Innovation Summit

Retrieved on: 
Wednesday, July 6, 2022
Timolol, Optic nerve, Retinitis pigmentosa, Patient, Glycogen storage disease, Lists of diseases, CGMP, Johns Hopkins School of Medicine, GLOBE, AAV, Retina, Hotel Edison, Investor, Technology, Edison Theatre, Cornea, AMD, Time, OIS, ODD, Diabetic retinopathy, Pharmaceutical industry

BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming Ophthalmology Innovation Source (OIS) Retina Innovation Summit, to be held in New York City on July 13, 2022.

Key Points: 
  • BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming Ophthalmology Innovation Source (OIS) Retina Innovation Summit, to be held in New York City on July 13, 2022.
  • Information about the event is listed below and available on the OIS Retina website.
  • Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases.
  • Founded in 2011 based on technology licensed from the Johns Hopkins University School of Medicine, Graybug has offices in Redwood City, California and in Baltimore, Maryland.

Graybug Announces Review of Strategic Alternatives

Retrieved on: 
Tuesday, June 28, 2022
Timolol, Review, Optic nerve, Retinitis pigmentosa, Board of directors, Acquisition, Patient, Glycogen storage disease, Lists of diseases, CGMP, Johns Hopkins School of Medicine, GLOBE, AAV, Sale, Retina, Company, U.S. Securities and Exchange Commission, Forward-looking statement, Piper Sandler Companies, Investment, Doctor of Pharmacy, Technology, Private Securities Litigation Reform Act, SEC, Cornea, AMD, Time, Board, ODD, Security (finance), Diabetic retinopathy, Pharmaceutical industry

BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.

Key Points: 
  • BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.
  • As part of this process, the Company will explore the potential for an acquisition, company sale, merger, divestiture of assets, private placement of equity securities, or other strategic transactions.
  • Graybug has retained Piper Sandler Companies to act as its financial advisor to assist with this review process.
  • Pending the outcome of this review, cost-containment measures are being put in place to maximize our cash resources available, said Frederic Guerard, PharmD, Chief Executive Officer of Graybug.

New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Retrieved on: 
Friday, June 24, 2022
Health, Pharmaceutical, Loss of Sensation, Science, Patient, NMOSD, EC, Union, Aquaporin 4, B cell, All European Academies, Royal commission, European Academy of Neurology, Quality of life, Attack, NMO, CD19, Optic nerve, Astrocyte, Pain scale, Spinal cord, Woman, Autoimmunity, Safety, Risk, Instagram, Congress, Twitter, Forward-looking statement, LinkedIn, Experiment, Brain, Poster, Severe cognitive impairment, European Commission, Central nervous system, Neuromyelitis optica spectrum disorder, Autoantibody, Inflammation, Nasdaq, Cell, EMEA, Courage, Adult, Head, Paralysis, U.S. Securities and Exchange Commission, Spectrum disorder, EAN, Physician, Pharmaceutical industry, Medical device, Vaccine, Wood drying, EU, Facebook

These data are being presented during the 8th Congress of the European Academy of Neurology (EAN), June 25-28 in Vienna.

Key Points: 
  • These data are being presented during the 8th Congress of the European Academy of Neurology (EAN), June 25-28 in Vienna.
  • Fewer NMOSD-related hospitalisations were reported among those receiving UPLIZNA compared to those treated with placebo (mean, EU: 1.0 vs 2.0; non-EU: 1.0 vs 1.33).
  • NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes.
  • Baranello RJ, Avasarala, JR. Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: Characterization, differential diagnosis, and recent advances.

High Potency Active Pharmaceutical Ingredient (HPAPI) Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 16, 2022
Biotechnology, Pharmaceutical, Health, Erectile dysfunction, Bristol Myers Squibb, Investor, Novartis, Safety, World, Environment, Death, Research, Efficiency, Glaucoma, Growth, CVD, Degenerative disease, API, Eye, Incidence, Organic, IARC, Optic nerve, Diabetes, Fine chemical, Pharmaceutical industry, Sanofi, Cancer

The "HP (High Potency) APIs Global Market Report 2022: By Type, By Synthesis, By Therapeutic" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HP (High Potency) APIs Global Market Report 2022: By Type, By Synthesis, By Therapeutic" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the high potency APIs (HPAPI) market are Eli Lily and Company; Novartis AG; Bristol-Myers Squibb Company; Roche Diagnostics Ltd; Sanofi.
  • The high potency APIs (HPAPI) market consists of sales of high potency active pharmaceutical ingredients and related services.
  • Therefore, large investment requirement acts as a major challenge for the growth of the high potency APIs market.

Ophthalmic Drugs Market Attract Notable Growth Prospects with Rising Awareness on Available Diagnosis and Treatment Solutions, Says TMR Study

Retrieved on: 
Thursday, June 16, 2022
Retinoblastoma, Solution, CAGR, Population, Infection, Therapy, Research report, Inflammation, Perception, Health care, Adoption, Globe, Growth, Transparency (market), Color, TMR, Eye, Glaucoma, Duane syndrome, Patient, Fast track (FDA), Awareness, Optic nerve, Pharmaceutical industry

These factors are expected to create lucrative prospects in the ophthalmic drugs market during the forecast period.

Key Points: 
  • These factors are expected to create lucrative prospects in the ophthalmic drugs market during the forecast period.
  • The global ophthalmic drugs market is likely to observe sluggish growth due to these disadvantages of the drugs.
  • These efforts are leading to surge in the sales growth in the global ophthalmic drugs market.
  • These factors, in turn, are generating sizable demand prospects in the global ophthalmic drugs market, notes TMR study.

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Retrieved on: 
Thursday, June 9, 2022
The Company, National Medical Products Administration, Degenerative disease, CDE, Company, Neuromyelitis optica spectrum disorder, Pemphigus vulgaris, Lupus, Research, NHL, Mab, Drug discovery, Safety, CD22, Epstein–Barr virus infection, SM03, RA, SLE, Central nervous system, Optic neuritis, Disease, Smoking, Center, Investigational New Drug, IND, Therapy, Optic nerve, NMPA, Spinal cord, Twelfth, PV, Thirteenth, Patient, MS, BTK, Rheumatoid arthritis, Incidence, Antibody, Union, IL-6, Multiple sclerosis, US, The Group, Center for Drug Evaluation and Research, EBV, Asthma, NMOSD, B-cell lymphoma, Recurrence, Pharmaceutical industry, Pemphigus, Phase

The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.

Key Points: 
  • The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.
  • The present IND submission, once granted, will enable the Company to conduct clinical program in China for treatment of NMOSD.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market in terms of mechanism of action, affinity, selectivity and safety.
  • An IND application for NMOSD for SN1011 of SinoMab has been accepted by the CDE of the NMPA, and once approved, will facilitate the clinical research and development of new drugs for NMOSD in China.

Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022

Retrieved on: 
Friday, June 3, 2022
Kepler, Johannes Kepler, ARVO, Eye, Company, Program, Journal, Euronext Paris, LLC, Ocular hypertension, Drainage, Safety, COX, Allergic conjunctivitis, Week, Pressure, Dolomites, Disease, 470, IOP, NO, Optic nerve, Therapy, Intraocular pressure, Severe cognitive impairment, Patient, AbbVie, Duane syndrome, NCX, Latanoprost, Bimatoprost, Efficiency, Fluticasone, Bausch & Lomb, Compartment, Nitric oxide, Pharmaceutical industry, Far East, Glaucoma, Mont Blanc

The Phase 2 efficacy results showed up to 1.4 mmHg superior intraocular pressure lowering with NCX 470 compared to latanoprost 0.005%.

Key Points: 
  • The Phase 2 efficacy results showed up to 1.4 mmHg superior intraocular pressure lowering with NCX 470 compared to latanoprost 0.005%.
  • The Mont Blanc trial is testing a higher concentration of NCX 470, and so could potentially demonstrate even greater efficacy.
  • Mont Blanc is a Phase 3 clinical trial in patients with elevated intraocular pressure due to open-angle glaucoma or ocular hypertension.
  • The Mont Blanc Phase 3 trial had an initial adaptive design period during which NCX 470 0.065% was evaluated together with the higher concentration of NCX 470 0.1%.

Soleo Health Named to Genentech’s Limited Drug Distribution Network for Provision of ENSPRYNG®

Retrieved on: 
Monday, June 6, 2022
Professional Services, Other Science, Research, Science, Practice Management, Nursing, Medical Supplies, Other Health, Managed Care, FDA, General Health, Diabetes, Radiology, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Software, Genetics, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, AIDS, Technology, Health, Surgery, Insurance, Caregiver, Time, Company, Facebook, ACHC, Genentech, Food, LinkedIn, Distinction, Pharmacist, Solution, Optic nerve, Spinal cord, Brain, Health, Patient, Autoimmune disease, Twitter, URAC, Food and Drug Administration, NMOSD, Joint Commission, Pharmaceutical industry

ENSPYRNG, a Food & Drug Administration-approved subcutaneous treatment, is administered by patients or caregivers every four weeks.

Key Points: 
  • ENSPYRNG, a Food & Drug Administration-approved subcutaneous treatment, is administered by patients or caregivers every four weeks.
  • We continue to forge integral, strong limited distribution partnerships with pharmaceutical manufacturers to aid in advancing the distribution and administration of many proven therapies.
  • In turn, our drug manufacturer partners find our services, clinical care and data highly advantageous to improving patient care, said Drew Walk, Soleo Health chief executive officer.
  • Soleo Health is an innovative national provider of complex specialty pharmacy services administered in the home or at alternate sites of care.

Insights on the Anti-Vascular Endothelial Growth Factor Therapeutics Global Market to 2030 - Featuring Amgen, Bausch Health Companies and Coherus Biosciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 2, 2022
General Health, Pharmaceutical, Optical, Health, Eli Lilly, Eye, Hoffmann-La Roche, US, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Neovascularization, US Foods, Ageing, MedImmune, Inc. v. Genentech, Inc., AMD, Therapy, Ranibizumab, US FDA, Optic nerve, NAMD, FDA, 938, Industry, Diabetic retinopathy, Faricimab, Vance DeGeneres, Pfizer, ABP, USD, Pharmaceutical industry, Fine chemical, Disease

The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 13.32 billion by 2030, according to a new study.

Key Points: 
  • The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 13.32 billion by 2030, according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The anti-vascular endothelial development aspect therapeutics industry is growing due to new product releases, FDA approvals, and research developments.
  • Market players such as Bausch Health Companies, Inc., Viatris, Inc., Amgen, Inc., Coherus Biosciences, Eli Lilly, F. Genentech Inc., Hoffmann-La Roche Ltd., Pfizer, Inc., and Xbrane Biopharma AB are some key players operating in the global anti-vascular endothelial growth factor therapeutics industry.